Please ensure Javascript is enabled for purposes of website accessibility

If You Invested $10,000 in Teladoc in January, This Is How Much You'd Have Now

By David Jagielski – Sep 26, 2020 at 7:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The virtual care stock doubled investor's money, and then some.

This year has been a transformative one for many industries. While many are facing new challenges related to the coronavirus pandemic, COVID-19 has also accelerated the growth of some industries. Healthcare is a great example of that, as the demand for telehealth has soared in 2020. The Business Group on Health's annual survey, which asks employers questions relating to healthcare, recently uncovered one notable trend: a rise in virtual care, or telehealth.

In 2018, just over half of respondents believed that virtual health would "play a significant role in how care is delivered in the future." That number grew to 80% this year. And 71% of employers are accelerating their adoption of virtual care and making it more available to employees.

One company that's benefiting from these trends is Teladoc Health (TDOC -3.40%). Let's take a look at just how well the company's done in 2020, and how much you would have made from investing in the stock at the start of the year.

Teladoc's been one of the hottest healthcare stocks of 2020

Year to date, shares of Teladoc are up around 150% -- nowhere near the S&P 500, which is practically flat after factoring in September's decline. To help put the company's impressive returns into perspective, let's assume you invested $10,000 into Teladoc at the beginning of the year when the healthcare stock was trading at $83. For that price, you'd be able to buy about 120 shares of the New York-based company. If you held on to those shares until today, as the stock's trading north of $215, your investment would be worth more than $26,000, making you a profit of $16,000.

Stethoscope and pen laying on a laptop.

Image source: Getty Images.

Why is the stock doing so well?

As noted earlier, Teladoc's been able to cash in on the growing demand for virtual care this year, and that's been behind the stock's strong returns thus far.

In the company's second-quarter results, released on July 29 for the period ended June 30, Teladoc reported 2.8 million total virtual visits over its platform -- a year-over-year increase of 203%. Its quarterly revenue of $241 million was also up by 85%. And while the knee-jerk reaction may be to say that these upticks are due only to COVID-19, that simply isn't the case. Teladoc CEO Jason Gorevic noted in the company's Q2 release that "in some states where the curve has flattened, we are still seeing twice as many patient visits as last year."

Even in the early stages of the pandemic, Teladoc was already seeing strong growth. In its first-quarter results, which the company released on April 29 for the period ended March 30, it recorded 2 million virtual care visits, up 92% from the prior-year period. Sales were also up 41% to $180.8 million.

Combined, over the past two quarters, patients have made 4.8 million physician visits on Teladoc's platform. That's more than the number of visits the company reported for the entire year of 2019 -- 4.1 million. And it's also on pace to smash last year's sales of $553.3 million. Year to date, sales are already at $421.8 million, which is more than 75% of 2019's total.

With numbers like that, it's not a mystery why Teladoc's stock has been performing so well.

More growth could be on the way for Teladoc

There's even more potential for Teladoc to build on these numbers, and that's because it's about to get bigger. On Aug. 5, the company announced it would merge with Livongo Health (LVGO) in a cash-and-stock deal worth $18.5 billion. The companies expect that the transaction will close before the end of the year and that it will create a stronger, more diverse virtual care company.

Livongo uses health coaches to help treat people with chronic conditions, including diabetes. Its intuitive and easy-to-use Livongo meter allows patients to stay connected to their doctors and families during COVID-19, easily sharing their glucose readings. Livongo's services could make a telehealth visit via Teladoc even more valuable, as shareable data means that a patient doesn't need to bring their meter to the doctor's office in order to receive care.

One of the most exciting aspects of the deal is that by joining together, Teladoc and Livongo can reach more customers. Gorevic estimates only a 25% overlap in existing customers between the two companies. This means that there is still room for cross-marketing once these companies join forces. And that can lead to even more growth. 

Is Teladoc still a good buy today?

Without the Livongo deal, it would be a tough call as to whether Teladoc is still worth investing in, especially as life slowly returns to normal and people begin to visit their doctors offices in-person again. That would likely bring down Teladoc's growth numbers.

But the merger with Livongo drastically changes things. With even more growth opportunities to tap into, there's reason to remain bullish on Teladoc today. And if there's a second wave of COVID-19 in the coming months, the new company will be in a terrific position to meet the needs of customers.

Although Teladoc has already generated some strong returns this year, the company isn't done growing, and is still a great stock to buy today.

David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Livongo Health Inc and Teladoc Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health Stock Quote
Teladoc Health
$27.60 (-3.40%) $0.97
Livongo Health Inc Stock Quote
Livongo Health Inc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.